Clinical Trial Update: Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia [Phase 3]

View source ↗

Summary

Reviva Pharmaceuticals' Brilaroxazine (RP5063) is in a Phase 3 schizophrenia trial assessing safety and efficacy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Brilaroxazine (RP5063)

Snippet

Sponsor: Reviva Pharmaceuticals | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING